Adempas: first soluble guanylate cyclase stimulator for pulmonary hypertension

Bayer has launched the first-in-class treatment Adempas (riociguat) to improve exercise capacity in adults with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY
Adempas (riociguat) provides a new treatment option for patient with pulmonary hypertension (pictured) | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Riociguat is a soluble guanylate cyclase (sGC) stimulator which has a dual mechanism of action. It sensitises sGC to endogenous nitric oxide (NO) by stabilising binding between sGC and NO and directly stimulates sGC independently of NO.

CLINICAL STUDIES

Riociguat has been studied in two key phase III clinical trials. The PATENT-1 study evaluated riociguat in patients with symptomatic pulmonary arterial hypertension and the CHEST-1 study assessed the efficacy and safety of riociguat for the treatment of chronic thromboembolic pulmonary hypertension that was inoperable or that had persisted or recurred after pulmonary endartectomy.

In both trials, patients were randomised to receive placebo or riociguat titrated over 8 weeks to optimal individual dose (range 500 microgram to 2.5mg three times daily), which was then maintained over a further 4 weeks in PATENT-1 and 8 weeks in CHEST-1. 

The primary endpoint, placebo-adjusted change from baseline in 6-minute walk distance, was 36 metres in PATENT-1 and 46 metres in CHEST-1 (p<0.0001 for both comparisons).

Headache, hypotension, GI upset, dizziness and peripheral oedema were the most commonly reported adverse effects.

View Adempas drug record

Further information: Bayer

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more